Tyra Biosciences, Inc. (TYRA) — Stock Valuation & Research

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase…

TYRA key statistics

Price$21.33
Market cap$1.27B
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range13.35-40.65
Beta0.75

Explore TYRA's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.